These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32719714)

  • 1. Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy.
    Passarelli C; Selvatici R; Carrieri A; Di Raimo FR; Falzarano MS; Fortunato F; Rossi R; Straub V; Bushby K; Reza M; Zharaieva I; D'Amico A; Bertini E; Merlini L; Sabatelli P; Borgiani P; Novelli G; Messina S; Pane M; Mercuri E; Claustres M; Tuffery-Giraud S; Aartsma-Rus A; Spitali P; T'Hoen PAC; Lochmüller H; Strandberg K; Al-Khalili C; Kotelnikova E; Lebowitz M; Schwartz E; Muntoni F; Scapoli C; Ferlini A
    Front Genet; 2020; 11():605. PubMed ID: 32719714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants.
    van den Bergen JC; Hiller M; Böhringer S; Vijfhuizen L; Ginjaar HB; Chaouch A; Bushby K; Straub V; Scoto M; Cirak S; Humbertclaude V; Claustres M; Scotton C; Passarelli C; Lochmüller H; Muntoni F; Tuffery-Giraud S; Ferlini A; Aartsma-Rus AM; Verschuuren JJ; 't Hoen PA; Spitali P
    J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1060-5. PubMed ID: 25476005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.
    Szabo SM; Salhany RM; Deighton A; Harwood M; Mah J; Gooch KL
    Orphanet J Rare Dis; 2021 May; 16(1):237. PubMed ID: 34022943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ; Roper H; Shaw NJ
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy of Duchenne Muscular Dystrophy.
    Hoffman EP
    Handb Exp Pharmacol; 2020; 261():25-37. PubMed ID: 31375923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients.
    Chen M; Wang L; Li Y; Chen Y; Zhang H; Zhu Y; He R; Li H; Lin J; Zhang Y; Zhang C
    Front Neurol; 2020; 11():721. PubMed ID: 32849198
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Kosac A; Pesovic J; Radenkovic L; Brkusanin M; Radovanovic N; Djurisic M; Radivojevic D; Mladenovic J; Ostojic S; Kovacevic G; Kravljanac R; Savic Pavicevic D; Milic Rasic V
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients.
    Capitanio D; Moriggi M; Torretta E; Barbacini P; De Palma S; Viganò A; Lochmüller H; Muntoni F; Ferlini A; Mora M; Gelfi C
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):547-563. PubMed ID: 31991054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy.
    Buckon CE; Sienko SE; Fowler EG; Bagley AM; Staudt LA; Sison-Williamson M; Heberer KR; McDonald CM; Sussman MD
    J Neuromuscul Dis; 2022; 9(2):321-334. PubMed ID: 34924398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup.
    Matsumoto M; Awano H; Lee T; Takeshima Y; Matsuo M; Iijima K
    Neuromuscul Disord; 2017 Nov; 27(11):1023-1028. PubMed ID: 28734761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy.
    Signorelli M; Ayoglu B; Johansson C; Lochmüller H; Straub V; Muntoni F; Niks E; Tsonaka R; Persson A; Aartsma-Rus A; Nilsson P; Al-Khalili Szigyarto C; Spitali P
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):505-517. PubMed ID: 31881125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.
    Liang WC; Wang CH; Chou PC; Chen WZ; Jong YJ
    Pediatr Neonatol; 2018 Apr; 59(2):176-183. PubMed ID: 28903883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
    Trifunov S; Natera-de Benito D; Exposito Escudero JM; Ortez C; Medina J; Cuadras D; Badosa C; Carrera L; Nascimento A; Jimenez-Mallebrera C
    Front Neurol; 2020; 11():304. PubMed ID: 32373058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
    Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients.
    Catapano F; Domingos J; Perry M; Ricotti V; Phillips L; Servais L; Seferian A; Groot I; Krom YD; Niks EH; Verschuuren JJ; Straub V; Voit T; Morgan J; Muntoni F
    Epigenomics; 2018 Jul; 10(7):875-889. PubMed ID: 29564913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of β
    Kelley EF; Cross TJ; Snyder EM; McDonald CM; ; Hoffman EP; Bello L
    Respir Res; 2019 Oct; 20(1):221. PubMed ID: 31619245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.